MaterIals and Methods
To provide complete specifications, the quality requirement must be related to the imprecision and inaccuracy of the measurement procedure and to the "sensitivity" of the QC procedure, i.e., its capability of detecting changes in the imprecision or inaccuracy of the measurement procedure (2). Specifications for imprecision, inaccuracy, and quality control are interdependent and must be considered together.
Our purpose in this paper is to describe sets of specifications that will ensure that cholesterol testing processes satisfy the NCEP requirements for quality at a stated level of confidence. To do this, we provide a model for setting QC procedures for use in the U.S. NCEP.
MaterIals and Methods

Model for Setting Process Specifications
The NCEP Adult Treatment Panel recommends classifying patients based on initial screening for total cholesterol and follow-up testing for low-density lipoprotein (LDL) cholesterol. In the initial step, the total cholesterol is measured for a nonfasting specimen and a patient is classified as follows: (a) A patient with a total cholesterol concentration s2000 mgfL (5.17 mmol/L) has a "desirable" cholesterol concentration means that all these components must be small enough that only 5% of the tail area of the distribution exceeds 2400 mgfL, the upper side of the medical decision interval. This model is similar to that described by Linnet (3) for relating a medical decision interval to the performance of the control procedure, but is presented in a form more consistent with the recent model of Fraser et al. (4) . The variance terms (those under the square root sign) account for the random components, whereas the linear terms account for systematic components. Although the systematic terms may sometimes be partly self-cancelling, it is advisable when planning an analytical process to consider the worst-case scenario and sum the absolute values of the bias terms. Figure 3a, AllowableImprecision (s Tables   1 and 2 , but not in Figures 2a or 2b) appears to ensure the necessary quality for single tests, and with N = 2 and N = 4 for two serial tests. However, the high false-rejection rate (9-16%) would increase the cost of operation and make these QC procedures impractical for most routine applications.
We conclude that a measurement procedure with CV 2.0% is generally needed with current QC procedures having N = 2 to assure the quality required for the U.S.
NCEP. This conclusion supports NCEP's efforts for improvement beyond the current 5% requirement, but indicates that the 3% goals for 1992 are not sufficient for single tests. However, the 3% goals are sufficient for two serial tests when current QC procedures are used with four control measurements per run.
Discussion
Our recommendations for laboratory process specifications differ from those of the NCEP because we consider both the stable (imprecision, inaccuracy) and unstable performance (the systematic error detectable by quality control) of a measurement procedure. NCEP guidelines assume stable performance and do not allow for the known lack of sensitivity of current QC procedures. In short, they specifr performance for an ideal situation, where the measurement procedure works unfailingly within the prescribed performance and no quality control is needed. Given the wide variety of testing sites, measurement systems, and different levels of operator skills in cholesterol testing today, it is unrealistic to assume ideal, stable operation. A QC procedure must be specified to detect with defined confidence those instances of unstable analytical performance. Although the QC design can be adapted to the actual frequency of problems that occur (9) (10) (11) , general recommendations and guidelines should not assume a zero frequency of errors or ideal stability.
Our model for setting process specifications also includes important pre-analytical factors, e.g., withinsubject biological variation, and can allow for sampling variation and sampling bias. These factors, which together with imprecision, inaccuracy, and QC sensitivity account for most of the potential changes in a test result, are related to the medical decision interval defined by the NCEP treatment plan. This model is consistent with Linnet' In applying this model, we have attempted to set input parameters to values consistent with those usedin earlier assessments by NCEP, e.g., a medical decision interval of 400 mg/L, a 6.5% CV for within-subject biological variation, analytical imprecision from 0.5% to 5%, and serial testing with two tests (6) . Thus, the specificationsderived should provide goodguidelines for selecting measurement and QC procedures that will accomplish the NCEP purposes in cholesterol testing. If the derived process specifications cannot be achieved by the existing analytical processes, the first consideration should be to improve the measurement procedure by reducing imprecision and eliminating analytical bias. Once optimal analytical performance is achieved, the QC procedure can be selected by following general design guidelines (9), optimizing for cost-effective operation based on process stability or frequency of errors (10, 11 
